Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 8 | 2024 | 61 | 1.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 447 | 0.620 |
Why?
|
| Vulvar Neoplasms | 2 | 2014 | 11 | 0.540 |
Why?
|
| Ovarian Neoplasms | 8 | 2025 | 148 | 0.510 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2005 | 141 | 0.450 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 345 | 0.430 |
Why?
|
| Cisplatin | 4 | 2024 | 139 | 0.410 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2011 | 257 | 0.280 |
Why?
|
| Paclitaxel | 2 | 2025 | 99 | 0.260 |
Why?
|
| Carcinoma, Endometrioid | 4 | 2019 | 21 | 0.240 |
Why?
|
| Sirolimus | 2 | 2016 | 92 | 0.220 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 66 | 0.210 |
Why?
|
| Female | 26 | 2025 | 32791 | 0.190 |
Why?
|
| Hysterectomy | 2 | 2017 | 69 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 102 | 0.180 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 159 | 0.170 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 15 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 1 | 1999 | 18 | 0.160 |
Why?
|
| Megestrol Acetate | 2 | 2016 | 3 | 0.150 |
Why?
|
| Tamoxifen | 2 | 2016 | 41 | 0.150 |
Why?
|
| Receptor, Notch2 | 1 | 2017 | 8 | 0.140 |
Why?
|
| Cervix Uteri | 1 | 1997 | 60 | 0.130 |
Why?
|
| Humans | 26 | 2025 | 63297 | 0.130 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2014 | 47 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2025 | 197 | 0.130 |
Why?
|
| Middle Aged | 12 | 2025 | 17553 | 0.130 |
Why?
|
| Preoperative Care | 2 | 2014 | 192 | 0.120 |
Why?
|
| Aged | 10 | 2025 | 14394 | 0.110 |
Why?
|
| Uterine Prolapse | 1 | 2014 | 16 | 0.110 |
Why?
|
| Colposcopy | 1 | 2014 | 20 | 0.110 |
Why?
|
| Endometrium | 1 | 2014 | 30 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2014 | 59 | 0.110 |
Why?
|
| Anaphylaxis | 1 | 1994 | 40 | 0.110 |
Why?
|
| Adult | 12 | 2025 | 16781 | 0.110 |
Why?
|
| Mass Screening | 1 | 1999 | 690 | 0.100 |
Why?
|
| Adnexal Diseases | 1 | 1993 | 8 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2017 | 491 | 0.100 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 129 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2013 | 123 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 141 | 0.090 |
Why?
|
| Herpes Zoster | 1 | 2011 | 24 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2013 | 287 | 0.090 |
Why?
|
| Lymphogranuloma Venereum | 1 | 1991 | 3 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2017 | 685 | 0.090 |
Why?
|
| Risk Factors | 3 | 2014 | 5343 | 0.090 |
Why?
|
| Epothilones | 1 | 2009 | 2 | 0.080 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 6 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2025 | 204 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 28 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2002 | 1618 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 5446 | 0.070 |
Why?
|
| Mutation | 1 | 2016 | 2607 | 0.070 |
Why?
|
| Postoperative Complications | 3 | 2017 | 1302 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 746 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 411 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 501 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2005 | 42 | 0.060 |
Why?
|
| Hemangiosarcoma | 1 | 2005 | 25 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2024 | 37 | 0.050 |
Why?
|
| Biopsy | 2 | 2014 | 444 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2004 | 70 | 0.050 |
Why?
|
| Neuralgia | 1 | 2003 | 21 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2024 | 3285 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2002 | 45 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 972 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2002 | 91 | 0.050 |
Why?
|
| Filgrastim | 1 | 2020 | 8 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 43 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 893 | 0.040 |
Why?
|
| Struma Ovarii | 1 | 1999 | 2 | 0.040 |
Why?
|
| Thyrotoxicosis | 1 | 1999 | 7 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 92 | 0.040 |
Why?
|
| Prognosis | 2 | 2002 | 1749 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 663 | 0.040 |
Why?
|
| Genetic Testing | 1 | 1999 | 134 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 1559 | 0.040 |
Why?
|
| Ileus | 1 | 2017 | 6 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 730 | 0.030 |
Why?
|
| Laparotomy | 1 | 2017 | 52 | 0.030 |
Why?
|
| Uterine Cervical Diseases | 1 | 1997 | 4 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2017 | 6630 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 1997 | 43 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 1997 | 56 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 91 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 278 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1999 | 311 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 115 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 152 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 10 | 0.030 |
Why?
|
| Postmenopause | 1 | 1997 | 237 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 84 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 171 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 199 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 524 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 290 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1994 | 124 | 0.030 |
Why?
|
| Ovarian Diseases | 2 | 2004 | 19 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 811 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 1993 | 11 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 242 | 0.030 |
Why?
|
| Torsion Abnormality | 1 | 1993 | 12 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 5656 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 298 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 1226 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 201 | 0.030 |
Why?
|
| Ovariectomy | 1 | 1993 | 103 | 0.030 |
Why?
|
| Morbidity | 1 | 1993 | 113 | 0.030 |
Why?
|
| Ovary | 1 | 1993 | 100 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2013 | 49 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 311 | 0.020 |
Why?
|
| Carcinoma | 1 | 1993 | 122 | 0.020 |
Why?
|
| Delirium | 1 | 2013 | 54 | 0.020 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1992 | 2 | 0.020 |
Why?
|
| Forecasting | 1 | 1993 | 232 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 196 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 1992 | 34 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 483 | 0.020 |
Why?
|
| Wound Healing | 1 | 2013 | 189 | 0.020 |
Why?
|
| Herpesvirus 3, Human | 1 | 2011 | 10 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 59 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 1997 | 2458 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 784 | 0.020 |
Why?
|
| Abdominal Wall | 1 | 2011 | 23 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2013 | 163 | 0.020 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 149 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2011 | 42 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 138 | 0.020 |
Why?
|
| Pain Management | 1 | 2013 | 161 | 0.020 |
Why?
|
| Pelvis | 1 | 1991 | 59 | 0.020 |
Why?
|
| Cohort Studies | 1 | 1997 | 2570 | 0.020 |
Why?
|
| Physical Examination | 1 | 1991 | 112 | 0.020 |
Why?
|
| Adolescent | 3 | 2004 | 6238 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1991 | 224 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2009 | 9 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2009 | 21 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 26 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2013 | 511 | 0.020 |
Why?
|
| Pregnancy | 2 | 1993 | 2330 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 1993 | 377 | 0.020 |
Why?
|
| Mesna | 1 | 2005 | 3 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2005 | 8 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2005 | 18 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 88 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 99 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 170 | 0.010 |
Why?
|
| Amitriptyline | 1 | 2003 | 7 | 0.010 |
Why?
|
| Fallopian Tube Diseases | 1 | 2003 | 6 | 0.010 |
Why?
|
| Child | 1 | 1993 | 4522 | 0.010 |
Why?
|
| Endometriosis | 1 | 2003 | 28 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 36 | 0.010 |
Why?
|
| Abscess | 1 | 2003 | 79 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 1121 | 0.010 |
Why?
|
| Thyroglobulin | 1 | 1999 | 9 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 1999 | 30 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 121 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 1543 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 2077 | 0.010 |
Why?
|
| Cystadenoma | 1 | 1993 | 7 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1993 | 10 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1993 | 42 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1992 | 10 | 0.010 |
Why?
|
| World Health Organization | 1 | 1992 | 34 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 79 | 0.010 |
Why?
|
| Alleles | 1 | 1993 | 447 | 0.010 |
Why?
|
| Methotrexate | 1 | 1992 | 80 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1992 | 118 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 1329 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 1990 | 0.010 |
Why?
|
| United States | 1 | 1992 | 7828 | 0.000 |
Why?
|